Bellicum Pharma (BLCM) Reports Q3 Loss Per Share of $0.51
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Tech stocks pull Wall Street lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Bellicum Pharmaceuticals Reports Third Quarter 2015 Financial Results and Recent Program Updates
November 9, 2015 4:05 PM ESTPediatric patients with beta thalassemia, SCID, and Wiskott-Aldrich Syndrome are disease-free following haplo transplant with BPX-501 T cells
Additional details of ongoing BPX-501 trial and adoptive T cell programs to be presented at ASH 2015
HOUSTON--(BUSINESS WIRE)-- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for cancers and orphan inherited blood disorders, today reported financial results for the third quarter of 2015 and provided an update on recent developments.
During the third... More
